|
1. Biologie
|
|
|
|
|
2. Etiologie
|
|
|
|
2.7 Etiologie - Obésité
|
|
|
|
3. Prévention
|
|
|
|
3.1 Tabac
|
|
|
|
|
3.6 Prévention - Activité physique
|
|
|
Pokémon no-go: game's exercise effects short-lived in most players [NHS Choices]
|
|
|
|
|
|
The
study takes advantage of technology not specifically aimed at improving
health, but with the potential to do so. Aside from the Pokémon game,
the researchers targeted participants with iPhones capable of recording
people's steps by default, rather than relying on people's estimates of
their walking time, or having to issue them with accelerometers.
|
|
|
|
|
|
|
4.12 Biopsies liquides
|
|
|
|
|
4.2 Dép., diag. & prono. - Génome
|
|
|
|
|
4.5 Dép., diag. & prono. - Colorectal
|
|
|
|
5. Traitements
|
|
|
|
|
5.10 Traitements - Essais
|
|
|
|
|
|
5.12.2 Immunothérapies - CAR-T
|
|
|
|
|
5.2 Pharma
|
|
|
|
5.2.1 Pharma - Partenariats
|
|
|
|
5.2.3 Pharma - économie
|
|
|
GSK chief: Immuno-oncology isn't cost-effective for global cancer treatment [FiercePharma]
|
|
|
|
|
|
Witty
continues to make the case that high-priced treatments don't make
business sense in the long run. Consider immuno-oncology. Speaking
Tuesday at the opening of GSK’s Rockville, Maryland, vaccine research
site, Witty said that he doesn’t see pricey immunotherapies for cancer,
now biopharma’s hottest field, as a “cost-effective … global healthcare
solution.”
|
|
|
|
|
|
|
|
5.3 Traitements - FDA, EMA, NICE...
|
|
|
|
New drug OKs fell off a cliff in 2016 and the FDA wants you to know why [EndPoints]
|
|
|
|
|
|
After
tracking surging new drug approvals for much of the past 5 years, which
helped alleviate concerns about the industry’s overall R&D
productivity rate, the agency posted only 19 new BLAs and NDAs in 2016 —
a low the agency hasn’t seen since the bad old days of 2007. The reason
for the sudden plunge, Jenkins explains in his presentation, has to do
with the fact that the FDA sped up 5 approvals, shifting them from 2016
up into 2015.
|
|
|
|
|
|
|
|
5.5 ASCO
|
|
|
|
6. Lutte contre les cancers
|
|
|
|
|
6.10.1 Politiques (USA)
|
|
|
A Closer Look at the 21st Century Cures Act [Cancer Research Catalyst]
|
|
|
|
|
|
It
is vitally important that NIH also receive robust, sustained, and
predictable funding increases through the regular appropriations
process. Therefore, the funding that is provided for the specific
initiatives that are included in 21st Century Cures must supplement, not
supplant, annual appropriations to the NIH, according to the AACR.
|
|
|
|
|
|
|
|
6.6 Publications
|
|
|
|
|
6.7 DMP, Big Data & applis
|
|
|
Should Big Data Pick Your Next Doctor? [Forbes]
|
|
|
|
|
|
The
company uses a database of some 700,000 physicians, 96% of the U.S.
total, and merges it with insurance-claims data and biographical
information to grade doctors based on the quality of their work.
|
|
|
|
|
|
|
6.7.1 Bioinformatique
|
|
|
|